Home - Research activities

The main research interest of the Molecular Carcinogenesis Group (MCG) is focused on deciphering the molecular mechanisms involved in the development of neoplastic disease.

The MCG has long been involved in the investigation of the mechanisms leading to deregulation of the cell cycle and the emergence of genomic instability in cancer [see achievements i-iv]. Aberrations in the pRb/E2F, DNA damage response and repair (DDR-R) and p53 pathways/networks have been the aims of intense research. Based on the extensive molecular pathology experience that the group possesses, notable clinic-pathological observations are functionally recapitulated in vitro and in vivo, aiming to decode the underlying mechanisms driving aberrant cellular behavior. Within this context we are particularly interested in the role of cellular senescence in cancer, and other age-related pathologies, as well [achievement v].

MCG is also investigating the role of inflammation during neoplastic as well as non-neoplastic diseases. We have contributed in unraveling the systemic impact of DNA damage response aberrations in inflammatory-driven cancer [achievement vi].

In the advent of digitized medicine where the size of data exponentially increases, machine learning frameworks are entering the scene allowing us to effectively utilize the massive amount of information generated on a daily basis. Consequently, we are developing  digital pathology tools that increase the efficiency and speed of diagnostic and therapeutic approaches and thus deliver personalized care opportunities for patients.

Within the frame of physiological and pathological human development we are interested also in human evolution. As a result and in collaboration with Professor Katerina Harvati, from the University of Tübingen, we published in Nature a series of important findings in the field of palaeoanthropology that are related to the early dispersal and presence of modern humans in Eurasia. Moreover, in a bone fragment adjacent to the human the skulls found we identified, using an innovative reagent that we developed [SenTraGor - see achievement v], the presence of lipofuscin a potent biomarker of senescence (Pharmacology –Therapeutics 2018). This finding depicts how resilient is lipofuscin to time and cellular degradation processes [achievement vii].

MCG has recently expanded its research interests towards Nanotechnology applications in human disease and life sciences. In collaboration with the Laboratory of General Chemistry at the National Technical University of Athens (N.T.U.A.), we aim to develop innovative nanoparticles with the potential to act as anticancer agents, in parallel with the discovery of advanced drug delivery systems for targeted therapeutic approaches.

Apart from the research activities, MCG is providing molecular pathology services. As an active collaborator of the European Society of Pathology, MCG is participating in the annually K-ras European Quality Assurance Program, related to the anti-EGFR therapy.

Major Achievements

Our group played a major role in:

i) Establishing the “Oncogene-induced DNA damage model for cancer development” (Science 2008; Nat Rev Mol Cell Biol 2010; J Pathol 2018) (Figures 1-6, 8). Based on: Nature 2005; Nature 2006; J Pathol 2006; Cancer Res 2007; Oncogene 2008; Blood 2008; Am J Pathol 2009; Cancer Res 2012; Cell Death Differ 2014; Cell Mol Life Sci 2014; Cell Rep 2015; Nat Cell Biol 2016; Genome Biology 2018; J Pathol 2018 and currently the broader role of DNA Damage response pathway in disease development (Cell 2016).

ii) Demonstrating that oncogene-induced senescence is a DNA damage stress response acting as a barrier to cancer (Nature 2006; Cancer Res 2007; Am J Pathol 2009; Curr Opin Cell Biol 2010; Nature Genetics 2011; Nature Cell Biol 2011; Cell Death Differ 2015; Nat Cell Biol 2016; BMC Genomics 2018; Genome Biology 2018) (Figures 2,5,6).

iii) Clarifying the functional interplay and the timeline of events underlying the two major antitumor checkpoint responses, i.e. DDR and ARF (Nat Cell Biol 2013; Cell Death Diff 2013; Cell Cycle 2014) (Figure 2).

iv) Revealing the oncogenic role of replication licensing factors Cdc6 and Cdt1 by inducing DNA replication stress and deregulating transcription (Am J Path 2004; Nature 2006; Cancer Res 2007, J Cell Biol 2011; Transcription 2012; Semin Cancer Biol 2016; Nat Commun 2016; Nat Cell Biol 2016; PNAS 2016; BMC Genomics 2018; Genome Biology 2018) (Figures 2-6).

v) Understanding how cellular senescence is involved in age-related pathologies, including cancer (EMBO J 2003; Lab Invest 2005; Nature 2006; Am J Pathol 2009; Mech Ageing Dev 2016; Aging 2013; Aging Cell 2013; Stem Cells 2013; Cell Death Differ 2015; Mech Ageing Dev 2016; Mech Ageing Dev 2018; Pharmacol Ther 2018; J Pathol 2018; Int. J. Mol. Sci. 2018) (Figures 2,5,6,8). Our research has led to the development of a pioneer senescence biomarker (commercially available under the trademark SenTraGorTM) able to detect senescence in any biological material including archival (Aging 2013; Aging Cell 2016; Pharmacol Ther 2018; Int. J. Mol. Sci. 2018; Meth Mol Biol 2019).

vi) Contributing to our understanding of the role that inflammation plays in cancer development (Cancer Cell 2013; Cancer Cell 2014; Pharmacol Ther 2015; Cell Rep 2016; Nat Commun 2018) (Figures 7,8).

vii) Providing evolutionary evidence that modern humans dispersed into Europe and Asia (150 thousand years) earlier than initially thought (Nature 2019) (Figure 9).

1. Mechanisms leading to genomic instability

Nat Rev Mol Cell Biol 2010

2. The role of the DNA damage response (DDR) pathway as an anti-tumor barrier

Science 2008
Nature 2005
Nature 2006
Nature Cell Biol 2013

3. The role of Cdc6 in cancer progression

 

Am J Pathol 2004
Cancer Res 2007
J Cell Biol 2011
Transcription 2012

4. Oncogenic Cdc6 as a molecular switch during cancer development

J Cell Biol 2011
Transcription 2012

5. Prolonged expression of p21WAF1/Cip1 in p53-null cells as a driving force for cancer progression

.

 

Re-replicating cell

Escaped and dividing cells

  Nat Cell Biol 2016

6. Proposed model depicting how p53-independent p21WAF1/Cip1 expression fuels Rad52–dependent error-prone double strand break repair promoting genomic instability

Model 6 Home page

 

RAD52 recruitment OFF cells.

RAD52 recruitment ON cells

Genome Biology 2018

7. The non cell-autonomous role of mutant p53 gain-of-function: reprogramming the microenvironment

Nat Commun 2018 Model 

ι) Cancer Cell & Microenvironment 2014
ιι) Nat Commun 2018

8. Proposed model depicting how oncogene induced replication stress aids the progressive formation of certain hallmarks of cancer (early events: steps 1-5), while paving the way for, angiogenesis, evasion from immune surveillance, invasion and metastasis (late events-6)

Model_8.jpg

J Pathol 2018

9. (a) Analysis of two human fossil skulls (Apidima 1 and Apidima2) found during excavations at Apidima cave in Mani, Peloponnese, showed that fossil find Apidima 1 was dated about 210.000 years old. It represented a modern human with archaic characteristics, indicating an early Homo sapiens. Apidima 2 was dated 170.000 years old, with Neanderthal features. These findings imply that early modern humans spread into Eurasia 150 thousand years earlier than thought.

 

(b) In a bone fragment (LAO1/S1) found adjacent to the human skull Apidima 1, we identified, using an innovative reagent (SenTraGor) that we developed, the presence of lipofuscin a potent biomarker of senescence.

a.

b.

Nature 2019 (a)
Pharmacology –Therapeutics 2018 (b)

VG New

Prof. Vassilis G. Gorgoulis

Laboratory of Histology-Embryology
Molecular Carcinogenesis Group
Medical School
National and Kapodistrian University of Athens

 

Biomedical Research Foundation of the Academy of Athens

 

Faculty Institute for Cancer Sciences, University of Manchester,
Manchester Academic Health Science Centre, Manchester, UK

Manchester Centre for Cellular Metabolism,
University of Manchester, Manchester Academic Health Science Centre, Manchester

 

EMBO member

Vassili G Gorgoulis: Loop-Frontiers

 

SenTraGorΤΜ

 

 

 

Office Tel: 0030 210-7462352
Fax: 0030 210-7462340
E-mail: vgorg@med.uoa.gr

Also see...

Copyright ©2011-2015, Prof. Gorgoulis Powered by AVMap